Google's Gemini AI Aims to 'Solve' Disease with Breakthrough Drug Discovery

Demis Hassabis, the pioneer behind Google's Gemini AI, shifts focus to using AI for drug design and development

Apr. 19, 2026 at 12:44pm

Got story updates? Submit your updates here. ›

A highly structured abstract painting in soft, flat colors featuring sweeping geometric arcs, concentric circles, and precise spirals, conceptually representing the complex scientific forces and concepts behind AI-driven drug discovery.Demis Hassabis' ambitious vision to harness AI for drug discovery could revolutionize the pharmaceutical industry and bring new hope to patients.Iowa City Today

Demis Hassabis, the visionary behind Google's Gemini AI system, has set his sights on an even more ambitious challenge - using artificial intelligence to revolutionize the field of drug discovery. With a deep fascination for the night sky and a background in AI, Hassabis is now leading Isomorphic Labs, a company dedicated to developing an AI-powered drug design engine that could dramatically accelerate the process of creating new, breakthrough medicines for some of the most difficult-to-treat diseases.

Why it matters

Hassabis' work at Isomorphic Labs has the potential to transform the pharmaceutical industry, saving years of research and development time while targeting diseases that have historically been resistant to treatment. By applying the same pattern-recognition and data-driven approaches that made Gemini a success, Hassabis aims to build a system that can design dozens of potential drug candidates each year, a feat that could revolutionize the notoriously slow and expensive drug discovery process.

The details

Hassabis' journey into drug discovery began with his fascination for the night sky and the patterns he saw in the constellations, which led him to explore the power of AI in identifying meaningful insights from vast datasets. Now, he's applying that same logic to the challenge of designing new drugs, focusing on targeting protein mutations and transcription factors that have proven difficult for traditional pharmaceutical approaches. With a strong team and backing from Alphabet, Isomorphic Labs is well-positioned to make a significant impact in the field of drug discovery.

  • Hassabis founded Isomorphic Labs in 2024 to pursue his vision of using AI for drug discovery.
  • The company has been actively developing its AI-powered drug design engine over the past two years.

The players

Demis Hassabis

The co-founder and CEO of Isomorphic Labs, a company dedicated to using AI for drug discovery. Hassabis previously founded DeepMind, the AI research company acquired by Google, and was the driving force behind the development of Google's Gemini AI system.

Isomorphic Labs

A biotechnology company founded by Demis Hassabis that is developing an AI-powered drug design engine to accelerate the process of creating new medicines for difficult-to-treat diseases.

Alphabet

The parent company of Google, which has provided backing and resources to support Isomorphic Labs' work in AI-driven drug discovery.

Got photos? Submit your photos here. ›

What they’re saying

“We must approach drug discovery with the same level of ambition and innovation that we've brought to other fields through the power of AI.”

— Demis Hassabis, Co-founder and CEO, Isomorphic Labs

“Isomorphic Labs' approach to drug design has the potential to dramatically accelerate the development of new treatments for some of the most challenging diseases.”

— Sundar Pichai, CEO, Alphabet

What’s next

Isomorphic Labs is currently in the process of testing its AI-powered drug design engine and plans to begin collaborating with pharmaceutical partners to bring its first drug candidates into clinical trials within the next 3-5 years.

The takeaway

Demis Hassabis' ambitious vision to 'solve' disease through the power of AI represents a significant shift in the pharmaceutical industry, with the potential to revolutionize the drug discovery process and bring new hope to patients suffering from some of the most intractable medical conditions.